{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T21:19:53Z","timestamp":1768079993085,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Key Program of National Natural Science Funds (NNSF) of China","award":["81830008"],"award-info":[{"award-number":["81830008"]}]},{"name":"the Key Program of National Natural Science Funds (NNSF) of China","award":["81830008"],"award-info":[{"award-number":["81830008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04001-7","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T08:30:22Z","timestamp":1742718622000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Be cautious to adopt a second CAR T-cell infusion after failure of CD19\/CD22 cocktail CAR T-cell therapy in relapsed\/refractory B-NHL"],"prefix":"10.1007","volume":"74","author":[{"given":"Gaoxiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meijuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuxia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dengju","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,22]]},"reference":[{"issue":"26","key":"4001_CR1","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1182\/blood-2014-03-563627","volume":"124","author":"D Hoelzer","year":"2014","unstructured":"Hoelzer D, Walewski J, D\u00f6hner H, Viardot A, Hiddemann W, Spiekermann K et al (2014) Improved outcome of adult Burkitt lymphoma\/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood 124(26):3870\u20133879","journal-title":"Blood"},{"issue":"2","key":"4001_CR2","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/bmt.2016.213","volume":"52","author":"N Schmitz","year":"2017","unstructured":"Schmitz N, Mounier N, Gill D, Linch D, Trneny M et al (2017) Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transp 52(2):216\u2013221","journal-title":"Bone Marrow Transp"},{"issue":"5","key":"4001_CR3","doi-asserted-by":"publisher","first-page":"836","DOI":"10.3109\/10428194.2011.643404","volume":"53","author":"D Telio","year":"2012","unstructured":"Telio D, Fernandes K, Ma C, Tsang R, Keating A, Crump M et al (2012) Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors. Leuk Lymphoma 53(5):836\u2013841","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"4001_CR4","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/ajh.23524","volume":"88","author":"SJ Nagle","year":"2013","unstructured":"Nagle SJ, Woo K, Schuster SJ, Nasta SD, Stadtmauer E, Mick R et al (2013) Outcomes of patients with relapsed\/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. Am J Hematol 88(10):890\u2013894","journal-title":"Am J Hematol"},{"issue":"6","key":"4001_CR5","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, Somerville T et al (2015) Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33(6):540\u2013549","journal-title":"J Clin Oncol"},{"issue":"1","key":"4001_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380(1):45\u201356","journal-title":"N Engl J Med"},{"key":"4001_CR7","doi-asserted-by":"publisher","first-page":"16002","DOI":"10.1038\/sigtrans.2016.2","volume":"1","author":"W Zhang","year":"2016","unstructured":"Zhang W, Wang Y, Guo Y, Dai H, Yang Q, Zhang Y et al (2016) Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report. Signal Transduct Target Ther 1:16002","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4001_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood.2019000017","volume":"135","author":"N Wang","year":"2020","unstructured":"Wang N, Hu X, Cao W, Li C, Xiao Y, Cao Y et al (2020) Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies. Blood 135(1):17\u201327","journal-title":"Blood"},{"issue":"3","key":"4001_CR9","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11523-020-00729-7","volume":"15","author":"S Ding","year":"2020","unstructured":"Ding S, Mao X, Cao Y, Wang N, Xu H, Zhou J (2020) Targeting CD79b for chimeric antigen receptor T-Cell therapy of B-Cell lymphomas. Target Oncol 15(3):365\u2013375","journal-title":"Target Oncol"},{"issue":"11","key":"4001_CR10","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1016\/j.bbmt.2019.06.036","volume":"25","author":"M Byrne","year":"2019","unstructured":"Byrne M, Oluwole OO, Savani B, Majhail NS, Hill BT, Locke FL (2019) Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 25(11):e344\u2013e351","journal-title":"Biol Blood Marrow Transplant."},{"issue":"10","key":"4001_CR11","doi-asserted-by":"publisher","first-page":"E273","DOI":"10.1002\/ajh.25591","volume":"94","author":"A Bukhari","year":"2019","unstructured":"Bukhari A, Chaer FE, Koka R, Singh Z, Hutnick E, Ruehle K et al (2019) Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss. Am J Hematol 94(10):E273\u2013E275","journal-title":"Am J Hematol"},{"issue":"13","key":"4001_CR12","first-page":"1832","volume":"137","author":"JY Spiege","year":"2021","unstructured":"Spiege JY, Dahiya S, Jain MD, Tamaresis J, Nastoupil LJ, Jacobs MT et al (2021) Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood 137(13):1832\u20131835","journal-title":"Blood"},{"issue":"9","key":"4001_CR13","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, Leeuwen DG, Drakes DJ et al (2018) Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol 36(9):847\u2013856","journal-title":"Nat Biotechnol"},{"issue":"7","key":"4001_CR14","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","volume":"23","author":"MP Avanzi","year":"2018","unstructured":"Avanzi MP, Yeku O, Li X, Wijewarnasuriya DP, Leeuwen DG, Cheung K et al (2018) Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system. Cell Rep 23(7):2130\u20132141","journal-title":"Cell Rep"},{"issue":"5","key":"4001_CR15","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","volume":"7","author":"D Alizadeh","year":"2019","unstructured":"Alizadeh D, Wong RA, Yang X, Wang D, Pecoraro J et al (2019) IL15 Enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol Res 7(5):759\u2013772","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"4001_CR16","doi-asserted-by":"publisher","first-page":"E209","DOI":"10.1002\/ajh.25505","volume":"94","author":"VA Chow","year":"2019","unstructured":"Chow VA, Gopal AK, Maloney DG, Turtle CJ, Smith SD, Ujjani CS et al (2019) Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. Am J Hematol 94(8):E209\u2013E213","journal-title":"Am J Hematol"},{"key":"4001_CR17","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1182\/blood-2019-126269","volume":"134","author":"M Shadman","year":"2019","unstructured":"Shadman M, Gauthier J, Khajavian S, Hirayama AV, Lynch RC, Smith SD et al (2019) Relapsed or Refractory CLL after CD19- Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes. Blood 134:4294","journal-title":"Blood"},{"issue":"1","key":"4001_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S et al (2018) CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med 24(1):20\u201328","journal-title":"Nat Med"},{"issue":"1","key":"4001_CR19","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12885-022-09489-1","volume":"22","author":"L An","year":"2022","unstructured":"An L, Lin Y, Deng B, Yin Z, Zhao D, Ling Z et al (2022) Humanized CD19 CAR-T cells in relapsed\/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy. BMC Cancer 22(1):393","journal-title":"BMC Cancer"},{"issue":"3","key":"4001_CR20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.17219\/acem\/145948","volume":"31","author":"J Mu","year":"2022","unstructured":"Mu J, Liu M, Wang J, Meng J, Zhang R, Jiang Y et al (2022) Successful treatment of second-time CAR-T 19 therapy after failure of first-time CAR-T 19 and ibrutinib therapy in relapsed mantle cell lymphoma. Adv Clin Exp Med 31(3):327\u2013335","journal-title":"Adv Clin Exp Med"},{"issue":"7","key":"4001_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1182\/blood.2020009515","volume":"138","author":"K Wudhikarn","year":"2021","unstructured":"Wudhikarn K, Flynn JR, Rivi\u00e8re I, G\u00f6nen M, Wang X, Senechal B et al (2021) Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy. Blood 138(7):531\u2013543","journal-title":"Blood"},{"issue":"9","key":"4001_CR22","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1182\/bloodadvances.2021006801","volume":"6","author":"S Gouni","year":"2022","unstructured":"Gouni S, Rosenthal AC, Crombie JL, Ip A, Kamdar MK, Hess B et al (2022) A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy. Blood Adv 6(9):2757\u20132762","journal-title":"Blood Adv"},{"issue":"5","key":"4001_CR23","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579\u2013586","journal-title":"J Clin Oncol"},{"issue":"6","key":"4001_CR24","doi-asserted-by":"publisher","first-page":"650","DOI":"10.6004\/jnccn.2019.0029","volume":"17","author":"AD Zelenetz","year":"2019","unstructured":"Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF et al (2019) NCCN Guidelines Insights: B-Cell Lymphomas. J Natl Compr Canc Netw 17(6):650\u2013661","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"4001_CR25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr (Engl Ed) 112(1):90\u201392","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"1","key":"4001_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40425-019-0529-9","volume":"7","author":"T Li","year":"2019","unstructured":"Li T, Zhang Y, Peng D, Mao X, Zhou X, Zhou J (2019) A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy. J Immunother Cancer 7(1):51","journal-title":"J Immunother Cancer"},{"issue":"23","key":"4001_CR27","doi-asserted-by":"publisher","first-page":"eabj2820","DOI":"10.1126\/sciadv.abj2820","volume":"8","author":"Z Bai","year":"2022","unstructured":"Bai Z, Woodhouse S, Zhao Z, Arya R, Govek K, Kim D et al (2022) Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. Sci Adv. 8(23):eabj2820","journal-title":"Sci Adv."},{"issue":"1","key":"4001_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/annonc\/mdj030","volume":"17","author":"KJ Savage","year":"2006","unstructured":"Savage KJ, Al-Rajhi N, Voss N, Paltiel C, Klasa R, Gascoyne RD et al (2006) Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol. 17(1):123\u2013130","journal-title":"Ann Oncol."},{"issue":"1","key":"4001_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1751-553X.2007.00900.x","volume":"30","author":"N Tomita","year":"2008","unstructured":"Tomita N, Kodama F, Motomura S, Itoh S, Ohshima R, Hyo R et al (2008) Adjuvant radiotherapy to an initial bulky mass in diffuse large B-cell lymphoma: lack of survival benefit. Int J Lab Hematol. 30(1):53\u201357","journal-title":"Int J Lab Hematol."},{"issue":"8","key":"4001_CR30","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 365(8):725\u2013733","journal-title":"N Engl J Med."},{"issue":"303","key":"4001_CR31","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DH Porter","year":"2015","unstructured":"Porter DH, Hwang W, Frey NV, Lacey SF, Shaw PA, Loren AW et al (2015) Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukaemia. Sci Transl Med. 7(303):303ra139","journal-title":"Sci Transl Med."},{"issue":"7","key":"4001_CR32","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Kochenderfer JN (2024) Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 21(7):501\u2013521","journal-title":"Nat Rev Clin Oncol."}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04001-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04001-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04001-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T10:48:53Z","timestamp":1745750933000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04001-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,22]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["4001"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04001-7","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,22]]},"assertion":[{"value":"13 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All authors consent to the publication of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study received approval from Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, and registered in the China Clinical Trials Registry (ChiCTR-OPN-16008526). All enrolled patients provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"156"}}